Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- AZ to Reduce US HQ Staff by approx. 400
October 11, 2011
- Cubicin 350 mg IV Inj. Launched for MRSA Infections: MSD
October 10, 2011
- Results of PIII Trial of Rotarix Published in US Journal Vaccine: GSK
October 10, 2011
- Tsuruha HD to Establish Drugstore Joint Venture in Thailand
October 10, 2011
- Teva, Kowa to Break Up Joint Venture After Just 3 Years
October 10, 2011
- MediciNova Announces Private Sale of Stock to Kissei
October 10, 2011
- Novartis Pharma Donates ¥21 Mil. for Free Medical Exams for Disaster Victims in Soma City
October 10, 2011
- Telavic Approved for Chronic Hepatitis C: MTPC
October 10, 2011
- Anti-emetic Proemend IV Infusion 150 mg Approved: Ono
October 10, 2011
- Ilaris Approved as Japan’s 1st CAPS Treatment: Novartis Pharma
October 10, 2011
- Teribone Approved for Osteoporosis with High Fracture Risk: Asahi Kasei Pharma
October 10, 2011
- TachoSil Tissue Sealing Sheet Approved: CSL Behring
October 10, 2011
- Avastin Receives Add’l Indication for Breast Cancer: Chugai
October 10, 2011
- Onyx Submits NDA in US for Carfilzomib in MM: Ono
October 10, 2011
- Eisai, Abbott Japan File for Additional Indication for Humira
October 10, 2011
- CHMP Issues Positive Opinion on New ARB Edarbi: Takeda
October 10, 2011
- Takeda Aims at New Drug Development through Open Innovation
October 7, 2011
- Takeda to Offer Information on Actos for Prescribing Doctors
October 7, 2011
- Takeda US Unit Withdraw sNDA for Velcade
October 7, 2011
- Mediceo Aiming for 20% Market Share in Hokkaido within 3 Years: President Watanabe
October 7, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…